Which has stronger earnings & valuation, VERA or ABVX?

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is VERA or ABVX more profitable?

Vera Therapeutics' return on equity of -74.86% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -74.86% -60.18% Abivax N/A -99.02% -70.26%

Does the media prefer VERA or ABVX?

In the previous week, Vera Therapeutics had 28 more articles in the media than Abivax. MarketBeat recorded 34 mentions for Vera Therapeutics and 6 mentions for Abivax. Abivax's average media sentiment score of 0.62 beat Vera Therapeutics' score of 0.56 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VERA or CYTK?

In the previous week, Vera Therapeutics had 26 more articles in the media than Cytokinetics. MarketBeat recorded 34 mentions for Vera Therapeutics and 8 mentions for Cytokinetics. Vera Therapeutics' average media sentiment score of 0.56 beat Cytokinetics' score of 0.43 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer IBRX or VERA?

In the previous week, Vera Therapeutics had 24 more articles in the media than ImmunityBio. MarketBeat recorded 34 mentions for Vera Therapeutics and 10 mentions for ImmunityBio. Vera Therapeutics' average media sentiment score of 0.56 beat ImmunityBio's score of 0.32 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, NUVL or VERA?

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A

Is NUVL or VERA more profitable?

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Vera Therapeutics N/A -74.86% -60.18%

Does the media prefer NUVL or VERA?

In the previous week, Vera Therapeutics had 24 more articles in the media than Nuvalent. MarketBeat recorded 34 mentions for Vera Therapeutics and 10 mentions for Nuvalent. Vera Therapeutics' average media sentiment score of 0.56 beat Nuvalent's score of 0.52 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 12 Very Positive mention(s) 5 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Vera Therapeutics (VERA) Competitors

$41.50 -0.50 (-1.19%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$40.90 -0.60 (-1.46%)

As of 07/13/2026 07:33 PM Eastern

Compare

VERA vs. ABVX, KRYS, CYTK, IBRX, and NUVL

Should you buy Vera Therapeutics stock or one of its competitors? MarketBeat compares Vera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vera Therapeutics include Abivax (ABVX), Krystal Biotech (KRYS), Cytokinetics (CYTK), ImmunityBio (IBRX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Vera Therapeutics compare to Abivax?

Vera Therapeutics (NASDAQ:VERA) and Abivax (NASDAQ:ABVX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Vera Therapeutics had 28 more articles in the media than Abivax. MarketBeat recorded 34 mentions for Vera Therapeutics and 6 mentions for Abivax. Abivax's average media sentiment score of 0.62 beat Vera Therapeutics' score of 0.56 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Vera Therapeutics' return on equity of -74.86% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Abivax	N/A	-99.02%	-70.26%

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vera Therapeutics currently has a consensus target price of $84.58, indicating a potential upside of 103.82%. Abivax has a consensus target price of $148.54, indicating a potential upside of 9.24%. Given Vera Therapeutics' higher possible upside, equities analysts plainly believe Vera Therapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Abivax	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

Vera Therapeutics beats Abivax on 9 of the 13 factors compared between the two stocks.

How does Vera Therapeutics compare to Krystal Biotech?

Vera Therapeutics (NASDAQ:VERA) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Vera Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

In the previous week, Vera Therapeutics had 33 more articles in the media than Krystal Biotech. MarketBeat recorded 34 mentions for Vera Therapeutics and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat Vera Therapeutics' score of 0.56 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Vera Therapeutics	Positive
Krystal Biotech	Very Positive

Krystal Biotech has a net margin of 53.92% compared to Vera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Krystal Biotech	53.92%	19.25%	17.62%

99.2% of Vera Therapeutics shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 13.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Vera Therapeutics currently has a consensus price target of $84.58, suggesting a potential upside of 103.82%. Krystal Biotech has a consensus price target of $352.00, suggesting a potential downside of 3.15%. Given Vera Therapeutics' higher possible upside, equities analysts plainly believe Vera Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59

Summary

Krystal Biotech beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Cytokinetics?

Vera Therapeutics (NASDAQ:VERA) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Vera Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

In the previous week, Vera Therapeutics had 26 more articles in the media than Cytokinetics. MarketBeat recorded 34 mentions for Vera Therapeutics and 8 mentions for Cytokinetics. Vera Therapeutics' average media sentiment score of 0.56 beat Cytokinetics' score of 0.43 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Vera Therapeutics presently has a consensus target price of $84.58, suggesting a potential upside of 103.82%. Cytokinetics has a consensus target price of $99.90, suggesting a potential upside of 21.47%. Given Vera Therapeutics' higher probable upside, equities research analysts clearly believe Vera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

Vera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Cytokinetics	-784.02%	N/A	-52.86%

Vera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vera Therapeutics beats Cytokinetics on 10 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Vera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Vera Therapeutics	N/A	-74.86%	-60.18%

ImmunityBio has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Vera Therapeutics has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	72.02	-$351.40M	-$0.85	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

ImmunityBio presently has a consensus price target of $14.20, indicating a potential upside of 82.28%. Vera Therapeutics has a consensus price target of $84.58, indicating a potential upside of 103.82%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Vera Therapeutics had 24 more articles in the media than ImmunityBio. MarketBeat recorded 34 mentions for Vera Therapeutics and 10 mentions for ImmunityBio. Vera Therapeutics' average media sentiment score of 0.56 beat ImmunityBio's score of 0.32 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vera Therapeutics beats ImmunityBio on 10 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Nuvalent has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 5.0% of Nuvalent shares are held by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Vera Therapeutics had 24 more articles in the media than Nuvalent. MarketBeat recorded 34 mentions for Vera Therapeutics and 10 mentions for Nuvalent. Vera Therapeutics' average media sentiment score of 0.56 beat Nuvalent's score of 0.52 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	12 Very Positive mention(s)	5 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Vera Therapeutics	N/A	-74.86%	-60.18%

Nuvalent currently has a consensus target price of $127.73, suggesting a potential upside of 3.06%. Vera Therapeutics has a consensus target price of $84.58, suggesting a potential upside of 103.82%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Summary

Vera Therapeutics beats Nuvalent on 10 of the 13 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.01B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-7.49	20.85	27.11	24.26
Price / Sales	N/A	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.89	8.49	10.75	6.29
Net Income	-$299.61M	$23.83M	$3.58B	$330.66M
7 Day Performance	-3.40%	-3.56%	-2.06%	-1.32%
1 Month Performance	21.13%	6.31%	3.32%	-0.64%
1 Year Performance	74.52%	48.30%	26.35%	19.08%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	3.4785 of 5 stars	$41.50 -1.2%	$84.58 +103.8%	+74.2%	$3.01B	N/A	N/A	40
ABVX Abivax	2.0605 of 5 stars	$143.99 -0.5%	$146.00 +1.4%	+1,544.3%	$11.54B	N/A	N/A	61
KRYS Krystal Biotech	2.6246 of 5 stars	$374.68 -0.1%	$340.56 -9.1%	+145.3%	$11.06B	$389.13M	50.09	210	Positive News Analyst Forecast
CYTK Cytokinetics	2.4789 of 5 stars	$85.57 -1.1%	$100.00 +16.9%	+122.2%	$10.76B	$88.04M	N/A	250
IBRX ImmunityBio	3.1908 of 5 stars	$8.91 -5.6%	$14.20 +59.4%	+177.2%	$9.89B	$113.29M	N/A	590	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. ABVX, KRYS, CYTK, IBRX, and NUVL

How does Vera Therapeutics compare to Abivax?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Summary

How does Vera Therapeutics compare to Cytokinetics?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Summary

How does Vera Therapeutics compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. ABVX, KRYS, CYTK, IBRX, and NUVL

How does Vera Therapeutics compare to Abivax?

Does the media prefer VERA or ABVX?

Which has more volatility and risk, VERA or ABVX?

Is VERA or ABVX more profitable?

Which has stronger earnings & valuation, VERA or ABVX?

Do institutionals and insiders believe in VERA or ABVX?

Do analysts recommend VERA or ABVX?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Which has more volatility and risk, VERA or KRYS?

Does the media refer more to VERA or KRYS?

Is VERA or KRYS more profitable?

Do insiders and institutionals believe in VERA or KRYS?

Do analysts prefer VERA or KRYS?

Which has stronger valuation and earnings, VERA or KRYS?

Summary

How does Vera Therapeutics compare to Cytokinetics?

Which has more risk & volatility, VERA or CYTK?

Does the media refer more to VERA or CYTK?

Do analysts prefer VERA or CYTK?

Is VERA or CYTK more profitable?

Which has better earnings & valuation, VERA or CYTK?

Do insiders & institutionals believe in VERA or CYTK?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Is IBRX or VERA more profitable?

Which has more volatility and risk, IBRX or VERA?

Which has preferable valuation and earnings, IBRX or VERA?

Do analysts recommend IBRX or VERA?

Do institutionals and insiders believe in IBRX or VERA?

Does the media prefer IBRX or VERA?

Summary

How does Vera Therapeutics compare to Nuvalent?

Which has more volatility and risk, NUVL or VERA?

Do institutionals & insiders believe in NUVL or VERA?

Does the media prefer NUVL or VERA?

Is NUVL or VERA more profitable?

Do analysts rate NUVL or VERA?

Which has stronger earnings and valuation, NUVL or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools